Eintrag weiter verarbeiten
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , |
| In: | Blood, 113, 2009, 20, S. 4992-5001 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Landgren, Ola Gilbert, Ethel S. Rizzo, J. Douglas Socié, Gérard Banks, Peter M. Sobocinski, Kathleen A. Horowitz, Mary M. Jaffe, Elaine S. Kingma, Douglas W. Travis, Lois B. Flowers, Mary E. Martin, Paul J. Deeg, H. Joachim Curtis, Rochelle E. Landgren, Ola Gilbert, Ethel S. Rizzo, J. Douglas Socié, Gérard Banks, Peter M. Sobocinski, Kathleen A. Horowitz, Mary M. Jaffe, Elaine S. Kingma, Douglas W. Travis, Lois B. Flowers, Mary E. Martin, Paul J. Deeg, H. Joachim Curtis, Rochelle E. |
|---|---|
| author |
Landgren, Ola Gilbert, Ethel S. Rizzo, J. Douglas Socié, Gérard Banks, Peter M. Sobocinski, Kathleen A. Horowitz, Mary M. Jaffe, Elaine S. Kingma, Douglas W. Travis, Lois B. Flowers, Mary E. Martin, Paul J. Deeg, H. Joachim Curtis, Rochelle E. |
| spellingShingle |
Landgren, Ola Gilbert, Ethel S. Rizzo, J. Douglas Socié, Gérard Banks, Peter M. Sobocinski, Kathleen A. Horowitz, Mary M. Jaffe, Elaine S. Kingma, Douglas W. Travis, Lois B. Flowers, Mary E. Martin, Paul J. Deeg, H. Joachim Curtis, Rochelle E. Blood Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation Cell Biology Hematology Immunology Biochemistry |
| author_sort |
landgren, ola |
| spelling |
Landgren, Ola Gilbert, Ethel S. Rizzo, J. Douglas Socié, Gérard Banks, Peter M. Sobocinski, Kathleen A. Horowitz, Mary M. Jaffe, Elaine S. Kingma, Douglas W. Travis, Lois B. Flowers, Mary E. Martin, Paul J. Deeg, H. Joachim Curtis, Rochelle E. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2008-09-178046 <jats:p>We evaluated 26 901 patients who underwent allogeneic hematopoietic cell transplantation (HCT) at 271 centers worldwide to define patterns of posttransplantation lymphoproliferative disorders (PTLDs). PTLDs developed in 127 recipients, with 105 (83%) cases occurring within 1 year after transplantation. In multivariate analyses, we confirmed that PTLD risks were strongly associated (P < .001) with T-cell depletion of the donor marrow, antithymocyte globulin (ATG) use, and unrelated or HLA-mismatched grafts (URD/HLA mismatch). Significant associations were also confirmed for acute and chronic graft-versus-host disease. The increased risk associated with URD/HLA-mismatched donors (RR = 3.8) was limited to patients with T-cell depletion or ATG use (P = .004). New findings were elevated risks for age 50 years or older at transplantation (RR = 5.1; P < .001) and second transplantation (RR = 3.5; P < .001). Lower risks were found for T-cell depletion methods that remove both T and B cells (alemtuzumab and elutriation, RR = 3.1; P = .025) compared with other methods (RR = 9.4; P = .005 for difference). The cumulative incidence of PTLDs was low (0.2%) among 21 686 patients with no major risk factors, but increased to 1.1%, 3.6%, and 8.1% with 1, 2, and more than 3 major risk factors, respectively. Our findings identify subgroups of patients who underwent allogeneic HCT at elevated risk of PTLDs for whom prospective monitoring of Epstein-Barr virus activation and early treatment intervention may be particularly beneficial.</jats:p> Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation Blood |
| doi_str_mv |
10.1182/blood-2008-09-178046 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDA4LTA5LTE3ODA0Ng |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDA4LTA5LTE3ODA0Ng |
| institution |
DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 |
| imprint |
American Society of Hematology, 2009 |
| imprint_str_mv |
American Society of Hematology, 2009 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
landgren2009riskfactorsforlymphoproliferativedisordersafterallogeneichematopoieticcelltransplantation |
| publishDateSort |
2009 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_unstemmed |
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_full |
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_fullStr |
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_full_unstemmed |
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_short |
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_sort |
risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2008-09-178046 |
| publishDate |
2009 |
| physical |
4992-5001 |
| description |
<jats:p>We evaluated 26 901 patients who underwent allogeneic hematopoietic cell transplantation (HCT) at 271 centers worldwide to define patterns of posttransplantation lymphoproliferative disorders (PTLDs). PTLDs developed in 127 recipients, with 105 (83%) cases occurring within 1 year after transplantation. In multivariate analyses, we confirmed that PTLD risks were strongly associated (P < .001) with T-cell depletion of the donor marrow, antithymocyte globulin (ATG) use, and unrelated or HLA-mismatched grafts (URD/HLA mismatch). Significant associations were also confirmed for acute and chronic graft-versus-host disease. The increased risk associated with URD/HLA-mismatched donors (RR = 3.8) was limited to patients with T-cell depletion or ATG use (P = .004). New findings were elevated risks for age 50 years or older at transplantation (RR = 5.1; P < .001) and second transplantation (RR = 3.5; P < .001). Lower risks were found for T-cell depletion methods that remove both T and B cells (alemtuzumab and elutriation, RR = 3.1; P = .025) compared with other methods (RR = 9.4; P = .005 for difference). The cumulative incidence of PTLDs was low (0.2%) among 21 686 patients with no major risk factors, but increased to 1.1%, 3.6%, and 8.1% with 1, 2, and more than 3 major risk factors, respectively. Our findings identify subgroups of patients who underwent allogeneic HCT at elevated risk of PTLDs for whom prospective monitoring of Epstein-Barr virus activation and early treatment intervention may be particularly beneficial.</jats:p> |
| container_issue |
20 |
| container_start_page |
4992 |
| container_title |
Blood |
| container_volume |
113 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348009701310466 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:04:22.081Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Risk+factors+for+lymphoproliferative+disorders+after+allogeneic+hematopoietic+cell+transplantation&rft.date=2009-05-14&genre=article&issn=1528-0020&volume=113&issue=20&spage=4992&epage=5001&pages=4992-5001&jtitle=Blood&atitle=Risk+factors+for+lymphoproliferative+disorders+after+allogeneic+hematopoietic+cell+transplantation&aulast=Curtis&aufirst=Rochelle+E.&rft_id=info%3Adoi%2F10.1182%2Fblood-2008-09-178046&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348009701310466 |
| author | Landgren, Ola, Gilbert, Ethel S., Rizzo, J. Douglas, Socié, Gérard, Banks, Peter M., Sobocinski, Kathleen A., Horowitz, Mary M., Jaffe, Elaine S., Kingma, Douglas W., Travis, Lois B., Flowers, Mary E., Martin, Paul J., Deeg, H. Joachim, Curtis, Rochelle E. |
| author_facet | Landgren, Ola, Gilbert, Ethel S., Rizzo, J. Douglas, Socié, Gérard, Banks, Peter M., Sobocinski, Kathleen A., Horowitz, Mary M., Jaffe, Elaine S., Kingma, Douglas W., Travis, Lois B., Flowers, Mary E., Martin, Paul J., Deeg, H. Joachim, Curtis, Rochelle E., Landgren, Ola, Gilbert, Ethel S., Rizzo, J. Douglas, Socié, Gérard, Banks, Peter M., Sobocinski, Kathleen A., Horowitz, Mary M., Jaffe, Elaine S., Kingma, Douglas W., Travis, Lois B., Flowers, Mary E., Martin, Paul J., Deeg, H. Joachim, Curtis, Rochelle E. |
| author_sort | landgren, ola |
| container_issue | 20 |
| container_start_page | 4992 |
| container_title | Blood |
| container_volume | 113 |
| description | <jats:p>We evaluated 26 901 patients who underwent allogeneic hematopoietic cell transplantation (HCT) at 271 centers worldwide to define patterns of posttransplantation lymphoproliferative disorders (PTLDs). PTLDs developed in 127 recipients, with 105 (83%) cases occurring within 1 year after transplantation. In multivariate analyses, we confirmed that PTLD risks were strongly associated (P < .001) with T-cell depletion of the donor marrow, antithymocyte globulin (ATG) use, and unrelated or HLA-mismatched grafts (URD/HLA mismatch). Significant associations were also confirmed for acute and chronic graft-versus-host disease. The increased risk associated with URD/HLA-mismatched donors (RR = 3.8) was limited to patients with T-cell depletion or ATG use (P = .004). New findings were elevated risks for age 50 years or older at transplantation (RR = 5.1; P < .001) and second transplantation (RR = 3.5; P < .001). Lower risks were found for T-cell depletion methods that remove both T and B cells (alemtuzumab and elutriation, RR = 3.1; P = .025) compared with other methods (RR = 9.4; P = .005 for difference). The cumulative incidence of PTLDs was low (0.2%) among 21 686 patients with no major risk factors, but increased to 1.1%, 3.6%, and 8.1% with 1, 2, and more than 3 major risk factors, respectively. Our findings identify subgroups of patients who underwent allogeneic HCT at elevated risk of PTLDs for whom prospective monitoring of Epstein-Barr virus activation and early treatment intervention may be particularly beneficial.</jats:p> |
| doi_str_mv | 10.1182/blood-2008-09-178046 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDA4LTA5LTE3ODA0Ng |
| imprint | American Society of Hematology, 2009 |
| imprint_str_mv | American Society of Hematology, 2009 |
| institution | DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T18:04:22.081Z |
| match_str | landgren2009riskfactorsforlymphoproliferativedisordersafterallogeneichematopoieticcelltransplantation |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 4992-5001 |
| publishDate | 2009 |
| publishDateSort | 2009 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Landgren, Ola Gilbert, Ethel S. Rizzo, J. Douglas Socié, Gérard Banks, Peter M. Sobocinski, Kathleen A. Horowitz, Mary M. Jaffe, Elaine S. Kingma, Douglas W. Travis, Lois B. Flowers, Mary E. Martin, Paul J. Deeg, H. Joachim Curtis, Rochelle E. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2008-09-178046 <jats:p>We evaluated 26 901 patients who underwent allogeneic hematopoietic cell transplantation (HCT) at 271 centers worldwide to define patterns of posttransplantation lymphoproliferative disorders (PTLDs). PTLDs developed in 127 recipients, with 105 (83%) cases occurring within 1 year after transplantation. In multivariate analyses, we confirmed that PTLD risks were strongly associated (P < .001) with T-cell depletion of the donor marrow, antithymocyte globulin (ATG) use, and unrelated or HLA-mismatched grafts (URD/HLA mismatch). Significant associations were also confirmed for acute and chronic graft-versus-host disease. The increased risk associated with URD/HLA-mismatched donors (RR = 3.8) was limited to patients with T-cell depletion or ATG use (P = .004). New findings were elevated risks for age 50 years or older at transplantation (RR = 5.1; P < .001) and second transplantation (RR = 3.5; P < .001). Lower risks were found for T-cell depletion methods that remove both T and B cells (alemtuzumab and elutriation, RR = 3.1; P = .025) compared with other methods (RR = 9.4; P = .005 for difference). The cumulative incidence of PTLDs was low (0.2%) among 21 686 patients with no major risk factors, but increased to 1.1%, 3.6%, and 8.1% with 1, 2, and more than 3 major risk factors, respectively. Our findings identify subgroups of patients who underwent allogeneic HCT at elevated risk of PTLDs for whom prospective monitoring of Epstein-Barr virus activation and early treatment intervention may be particularly beneficial.</jats:p> Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation Blood |
| spellingShingle | Landgren, Ola, Gilbert, Ethel S., Rizzo, J. Douglas, Socié, Gérard, Banks, Peter M., Sobocinski, Kathleen A., Horowitz, Mary M., Jaffe, Elaine S., Kingma, Douglas W., Travis, Lois B., Flowers, Mary E., Martin, Paul J., Deeg, H. Joachim, Curtis, Rochelle E., Blood, Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation, Cell Biology, Hematology, Immunology, Biochemistry |
| title | Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_full | Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_fullStr | Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_full_unstemmed | Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_short | Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_sort | risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| title_unstemmed | Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2008-09-178046 |